Healthcare Industry News:  benign prostatic hyperplasia 

Biopharmaceuticals Urology

 News Release - March 19, 2007

Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J.--(HSMN NewsFeed)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX ) today announced positive results from its newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 26 clinical trial sites across the U.S. and 116 unselected subjects participated in the blinded, placebo controlled study.

The study assessed symptom scores and treatment outcome 8-19 months after NX-1207 treatment. Overall, without further NX-1207 treatment, patients initially treated with NX-1207 showed a total pooled mean improvement of 7.4 points in the primary outcome endpoint of AUA Symptom Score values, which reached statistical significance when compared with the placebo control (p=.028).

In terms of treatment outcomes, patients treated with NX-1207 had statistically significantly more (p=.02) favorable outcomes compared to placebo.

There have been no significant sexual side effects from NX-1207.

Paul Averback MD, CEO of Nymox said, "Nymox is continuing to carefully move this drug ahead as rapidly as possible. This placebo-controlled blinded clinical study demonstrates a striking degree of long-term improvement in BPH patients given NX-1207, and confirms the promising results from the earlier completed U.S. clinical trials."

Dr. Averback added, "The durability of BPH symptom improvement from NX-1207 treatment is clearly shown by this new data, which is of special interest to potential marketing partners for NX-1207."

The Company previously completed three U.S. trials for NX-1207, including most recently a Phase 2 double-blind, placebo controlled, randomized multi-site U.S. study, which showed positive efficacy and safety results for NX-1207 after 3 months in patients with BPH. Overall, patients treated with NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 point reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.

The AUA Symptom Score is a standardized measurement of BPH symptoms and includes data on 1) sensations of incomplete emptying of the bladder; 2) need to urinate frequently; 3) stopping and starting during urination; 4) urgent need to urinate; 5) weakness of urinary stream; 6) need to push or strain during urination; and 7) urination during sleep (nocturia). Published studies of currently approved drugs for BPH show AUA Symptom Score improvement in the 3.5 to 5 point range.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.


Source: Nymox Pharmaceutical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.